Article
The IIF designation was added to include cystic lesions that are slightly more complex than category II, but that do not fulfill criteria of category III.
Casdatifan is linked with promising safety, efficacy in clear cell RCC
Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
Disitamab vedotin plus toripalimab shows safety, efficacy in MIBC
Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC
EV/pembrolizumab continues to show OS, PFS benefit vs chemotherapy in la/mUC
Additional NIAGARA data spotlight benefits of durvalumab plus chemo for MIBC